Cargando…
Safety and tolerability of obeticholic acid in chronic liver disease: a pooled analysis of 1878 individuals
Obeticholic acid (OCA) is a farnesoid X receptor agonist used in primary biliary cholangitis (PBC) treatment. Recent studies have expanded OCA use for NASH treatment and results from phase 3 clinical trial have shown beneficial reduction of ≥1 stage of fibrosis with no NASH worsening. However, safet...
Autores principales: | Ng, Cheng Han, Tang, Ansel Shao Pin, Xiao, Jieling, Wong, Zhen Yu, Yong, Jie Ning, Fu, Clarissa E., Zeng, Rebecca W., Tan, Caitlyn, Wong, Gabriel Hong Zhe, Teng, Margaret, Chee, Douglas, Tan, Darren Jun Hao, Chan, Kai En, Huang, Daniel Q., Chew, Nicholas W.S., Nah, Benjamin, Siddqui, Mohammad S., Sanyal, Arun J., Noureddin, Mazen, Muthiah, Mark |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9915961/ https://www.ncbi.nlm.nih.gov/pubmed/36757421 http://dx.doi.org/10.1097/HC9.0000000000000005 |
Ejemplares similares
-
Depression in non-alcoholic fatty liver disease is associated with an increased risk of complications and mortality
por: Ng, Cheng Han, et al.
Publicado: (2022) -
A poor perspective of self weight significantly increases adverse outcomes in non-alcoholic fatty liver disease (NAFLD)
por: Fu, Clarissa Elysia, et al.
Publicado: (2022) -
DEXA Scan Body Fat Mass Distribution in Obese and Non-Obese Individuals and Risk of NAFLD—Analysis of 10,865 Individuals
por: Tan, Caitlyn, et al.
Publicado: (2022) -
Drug discovery and treatment paradigms in nonalcoholic steatohepatitis
por: Noureddin, Mazen, et al.
Publicado: (2019) -
A Class Effect Network Meta-analysis of Lipid Modulation in Non-alcoholic Steatohepatitis for Dyslipidemia
por: Xiao, Jieling, et al.
Publicado: (2022)